Biopharmaceutical company Sinovac Biotech Ltd announced on Wednesday that it will offer its inactivated COVID-19 vaccine, CoronaVac, to self-paying groups in Hong Kong and will also donate vaccines to local charity groups to provide children access to free vaccines.
Hong Kong authorities have said that high-risk groups will receive free doses of the COVID-19 vaccine, while low-risk groups, including children, can only receive their vaccines via the private market.
CoronaVac is authorised for use in more than 60 countries and regions, with the cumulative global supply exceeding 2.9 billion doses. Published studies show that CoronaVac has a good safety profile for healthy people, effectively reducing severe illness and deaths related to COVID-19. Adults vaccinated with three doses showed more than 90% protection against serious or fatal illness during the outbreak of the omicron variant in Hong Kong.
In children aged 3 to 18 who received two doses, the vaccine's effectiveness against moderate to severe disease has been shown to be as high as 95.8%. To address the needs of low-risk groups, including children, Sinovac will provide thousands of free doses of CoronaVac for children aged 3 to 12 in Hong Kong.
The company added that it is seeking opportunities for collaboration to explore the feasibility of free vaccination. In markets where inactivated COVID-19 vaccines for children are limited, Sinovac is offering a viable solution for parents who prefer the safety and effectiveness of inactivated vaccines.
Replicate Bioscience begins phase one trial of RBI-4000 vaccine
Moderna and Immatics form strategic collaboration to develop new oncology therapies
Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine receives positive CHMP opinion in EU
Valneva's chikungunya vaccine moves forward with Health Canada's review
Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
Anixa Biosciences advances ovarian cancer CAR-T trial with third patient
GC Biopharma signs MoU with GC Biopharma for co-production of Euvichol
GC Biopharma partners with Eubiologics for joint cholera vaccine production
GSK's Shingrix shows 100% efficacy against shingles in Chinese adults
Pfizer's Abrysvo receives FDA approval for pregnant individuals to prevent RSV in infants
Arcturus' mRNA manufacturing partner ARCALIS receives USD115m in grants from the Japanese government
Roquefort Therapeutics boosts patent portfolio with PCT Filing